LYEL
Lyell Immunopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$508.09M
P/E Ratio
—
EPS
$-16.06
Beta
-0.07
52W High
$45.00
52W Low
$7.65
50-Day MA
$22.83
200-Day MA
$18.63
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Fundamentals
| Revenue (TTM) | 36,000 |
| Gross Profit (TTM) | 36,000 |
| EBITDA | $-186.75M |
| Operating Margin | -1024633.00% |
| Return on Equity | -87.00% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.68 |
| Price-to-Book | 1.98 |
| Price-to-Sales (TTM) | 14113.68 |
| EV/Revenue | 8209.85 |
| EV/EBITDA | 0.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -45.50% |
| Shares Outstanding | $23.33M |
| Float | $13.91M |
| % Insiders | 25.25% |
| % Institutions | 53.69% |
Analyst Ratings
Consensus ($32.50 target)
2
Buy1
Strong SellData last updated: 4/8/2026